Lead Product(s) : Fotemustine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Servier | UNICANCER
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2016
Lead Product(s) : Fotemustine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Servier | UNICANCER
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fotemustine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2015
Lead Product(s) : Fotemustine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fotemustine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2011
Lead Product(s) : Fotemustine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable